Evidence map›Paper›PMID 8622667›Full record

ArticleMolecular and cellular biology1996

CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter.

D E Zhang, C J Hetherington, S Meyers, K L Rhoades, C J Larson, H M Chen, S W Hiebert, D G Tenen

Open access · greenAbstract read
In one paragraph

Article in Molecular and cellular biology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 150 papers.

0numbers the graph read from it
0cells of the map it votes in
150citing papers in PubMed
16.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

150 citing papers in PubMed, 399 citations in OpenAlex.

  1. Article
  2. Synergistic adverse prognosis ofFrontiers in cell and developmental biology · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Prostaglandin EStem cell reviews and reports · 2021
    Article
  13. Article
  14. Article
  15. Article
  16. RUNX1-ETO: Attacking the Epigenome for Genomic Instable Leukemia.International journal of molecular sciences · 2019
    Review
  17. Article
  18. Article
  19. Article
  20. Article

90 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

D E ZhangDepartment of Medicine, Beth Israel Hospital and Harvard Medical School, Boston, Massachusetts 02215, USA.
C J Hetherington
S Meyers
K L Rhoades
C J Larson
H M Chen
S W Hiebert
D G Tenen
Beth Israel Deaconess Hospital · USHarvard University · USSt. Jude Children's Research Hospital · USSalk Institute for Biological Studies · US

Funding

Role of AML1-ETO in Acute LeukemiaR01CA064140 · NCI · VANDERBILT UNIVERSITY · PI HIEBERT, SCOTT W · 1994 to 2018
$5.7M
MOLECULAR BIOLOGY OF MYELOID DIFFERENTIATIONR01CA041456 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI TENEN, DANIEL G · 1986 to 2010
$4.6M
CD14 REGULATION BY MONOCYTE DIFFERENTIATION &CYTOKINESR29CA059589 · NCI · SCRIPPS RESEARCH INSTITUTE · PI ZHANG, DONG-ER · 1994 to 1998
–
NCI NIH HHS CA41456NCI NIH HHS CA64140NCI NIH HHS CA/AI59589
6 · The paper itself

Abstract

Transcription factors play a key role in the development and differentiation of specific lineages from multipotential progenitors. Identification of these regulators and determining the mechanism of how they activate their target genes are important for understanding normal development of monocytes and macrophages and the pathogenesis of a common form of adult acute leukemia, in which the differentiation of monocytic cells is blocked. Our previous work has shown that the monocyte-specific expression of the macrophage colony-stimulating factor (M-CSF) receptor is regulated by three transcription factors interacting with critical regions of the M-CSF receptor promoter, including PU.1 and AML1.PU.1 is essential for myeloid cell development, while the AML1 gene is involved in several common leukemia-related chromosome translocations, although its role in hematopoiesis has not been fully identified. Along with AML1, a third factor, Mono A, interacts with a small region of the promoter which can function as a monocyte-specific enhancer when multimerized and linked to a heterologous basal promoter. Here, we demonstrate by electrophoretic mobility shift assays with monocytic nuclear extracts, COS-7 cell-transfected factors, and specific antibodies that the monocyte-enriched factor Mono A is CCAAT enhancer-binding protein (C/EBP). C/EBP has been shown previously to be an important transcription factor involved in hepatocyte and adipocyte differentiation; in hematopoietic cells, C/EBP is specifically expressed in myeloid cells. In vitro binding analysis reveals a physical interaction between C/EBP and AML1. Further transfection studies show that C/EBP and AML1 in concert with the AML1 heterodimer partner CBF beta synergistically activate M-CSF receptor by more then 60 fold. These results demonstrate that C/EBP and AML1 are important factors for regulating a critical hematopoietic growth factor receptor, the M-CSF receptor, suggesting a mechanism of how the AML1 fusion protein could contribute to acute myeloid leukemia. Furthermore, they demonstrate physical and functional interactions between AML1 and C/EBP transcription factor family members.

Indexed as

Proto-Oncogene ProteinsAnimalsBase SequenceCCAAT-Enhancer-Binding ProteinsCell LineCore Binding Factor Alpha 2 SubunitDNA-Binding ProteinsHumansMolecular Sequence DataMonocytesNeoplasm ProteinsNuclear ProteinsPromoter Regions, GeneticProtein BindingReceptor, Macrophage Colony-Stimulating FactorSignal TransductionCCAAT-Enhancer-Binding ProteinsCore Binding Factor Alpha 2 SubunitDNA-Binding ProteinsNeoplasm ProteinsNuclear ProteinsProto-Oncogene ProteinsReceptor, Macrophage Colony-Stimulating FactorRUNX1 protein, humanTranscription Factors

Identifiers

PMID8622667
PMCPMC231105
OpenAlexW2165787335

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.